Preview

Исследования и практика в медицине

Расширенный поиск

Возможности сочетания иммунотерапии с лучевой терапией в лечении больных неоперабельным местно-распространённым немелкоклеточным раком легкого. Обзор литературы.

Аннотация

На сегодняшний день рак легкого является одной из самых актуальных проблем онкологии в мире. В лечении неоперабельных форм немелкоклеточного рака легкого оптимальным методом остается химиолучевое лечение. Одной из новых возможностей лекарственной терапии, которая показывает улучшение показателя общей выживаемости при раке легкого, является терапия ингибиторами контрольных точек иммунного ответа - моноклональных антител, которые блокируют иммуносупрессивные белки, повышающие регуляцию на поверхности Т-клеток и улучшающие собственную иммунную систему пациента для реагирования на опухолевые клетки. В 2019 году в клиническую практику внедрен препарат дурвалумаб для лечения пациентов с неоперабельной III стадией НМРЛ, достигших, по крайней мере, стабилизации заболевания после проведенного химиолучевого лечения.

В данной работе представлены исследования, изучающие проведение лучевой терапии с различными группами препаратов, оказывающих влияние на контрольные точки иммунного ответа.

Об авторе

Евгений Игоревич Смоленов
Медицинский радиологический научный центр им. А.Ф. Цыба - филиал федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской Федерации.
Россия

Кандидат медицинских наук

Научный сотрудник отделения лучевого и хирургического лечения заболеваний   торакальной области МРНЦ им. А.Ф. Цыба – филиал ФГБУ “НМИЦ радиологии” МЗ РФ



Список литературы

1. Состояние онкологической помощи населению России в 2019 г. [Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой]. М. 2020: 236 с.

2. Рагулин Ю.А. Сочетание иммунотерапии и лучевой терапии при немелкоклеточном раке легкого. Онкология. Журнал им. П.А. Герцена. 2018; 7(5): 90-96. https://doi.org/10.17116/onkolog2018705190

3. Руководство по химиотерапии опухолевых заболеваний [Под ред. Н. И. Переводчиковой, В.А. Горбуновой]. M.: Практическая медицина. 2015. 686 с

4. NCCN.org. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for non-small cell lung cancer V.3.2020. © National Comprehensive Cancer Network, Inc.; 2020.

5. Рагулин Ю.А., Смоленов Е.И., Усачев В.С., Афонин Г.В. Таргетная терапия местно-распространенного немелкоклеточного рака легкого с EGFR – мутацией. Онкология. Журнал им. П.А. Герцена. 2016; 5(2): 48-53. https://doi.org/10.17116/onkolog20165248-53

6. Ассоциация онкологов России. Клинические рекомендации “Злокачественное новообразование бронхов и легкого” [Под ред. А.Д. Каприна] М. 2020. 90 с.

7. Родионов Е.О., Миллер С.В, Тузиков С.А., Ефтеев Л.А., Маркович В.А., Миллер С.А. Иммунотерапия рецидивного немелкоклеточного рака легкого в первой линии. Медицинский совет. 2019; 19:132-136. https://doi.org/10.21518/2079-701X-2019-19-132-136

8. Болотина Л. В., Каприн А. Д. Иммуноонкология: новые горизонты лекарственной терапии солидных опухолей. Онкология. Журнал им. П.А. Герцена. 2017;6(5):74-80. https://doi.org/10.17116/onkolog20176574-80

9. Сакаева Д.Д., Ручкин В.В., Гончарова О.В., Аббасова Р.Р., Муфазалов Ф.Ф.

10. Дурвалумаб в терапии местно-распространенного немелкоклеточного рака легкого после химиолучевого лечения в реальной практике. Современная онкология. 2019; 21(3); 21-25. https://doi.org/10.26442/18151434.2019.3.190679

11. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1–27.

12. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases: a literature review. Cancer 1971;28:89–98. https://doi.org/10.1002/1097-0142(197107)28:1<89::aid-cncr2820280117>3.0.co;2-q

13. Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, Pirker R, Douillard JY, Le Chevalier T, Filipits M, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol 2016;34:1223–1230. https://doi.org/10.1200/JCO.2015.63.0970

14. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991–998. https://doi.org/10.1038/ni1102-991

15. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis 2015;6:e1792. https://doi.org/10.1038/cddis.2015.162

16. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13:227–242. https://doi.org/10.1038/nri3405

17. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975;53:27–42. https://doi.org/10.1038/icb.1975.3

18. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009;229:12–26. https://doi.org/10.1111/j.1600-065X.2009.00770.x.

19. Лактионов К.К., Саранцева К.А., Бредер В.В., Окружнова М.А., Перегудова М.В. Место иммуноонкологии в лечении немелкоклеточного рака легкого. Злокачественные опухоли. 2016, 3: 17-24. https://doi.org/10.18027/2224-5057-2016-3-17-24

20. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–182. https://doi.org/10.1111/j.1600-065X.2008.00662.x.

21. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA. 1997;94:8099–8103. https://doi.org/10.1073/pnas.94.15.8099

22. Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2010;140:377–86. https://doi.org/10.1016/j.jtcvs.2009.12.054

23. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28:928–35. https://doi.org/10.1200/JCO.2009.25.0928

24. O'Rourke N, Roqué IFM, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010:CD002140.

25. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90. https://doi.org/10.1200/JCO.2009.26.2543

26. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–99 https://doi.org/10.1016/S1470-2045(14)71207-0

27. Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, et al. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2013;85:1325–1331. https://doi.org/10.1016/j.ijrobp.2012.11.011

28. Hepel JT, Leonard KL, Safran H, Ng T, Taber A, Khurshid H, et al. Stereotactic body radiation therapy boost after concurrent chemoradiation for locally advanced non-small cell lung cancer: a phase 1 dose escalation study. Int J Radiat Oncol Biol Phys. 2016;96:1021–1027. https://doi.org/10.1016/j.ijrobp.2016.08.032

29. Higgins KA, Pillai RN, Chen Z, Tian S, Zhang C, Patel P, et al. Concomitant chemotherapy and radiotherapy with SBRT boost for unresectable, stage III non-small cell lung cancer: a phase I study. J Thorac Oncol. 2017;12:1687–1695. https://doi.org/10.1016/j.jtho.2017.07.036

30. Kumar S, Feddock J, Li X, Hall L, Shelton BJ, Arnold S, et al. An update of a prospective study of SBRT for postchemoradiation residual disease in stage II/III nonsmall cell lung cancer. Radiat Oncol. 2017;99:652–659. https://doi.org/10.1016/j.ijrobp.2017.07.036

31. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81:1352–1358. https://doi.org/10.1016/j.ijrobp.2009.07.1751

32. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070–1076. https://doi.org/10.1001/jama.2010.261

33. Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016;40:25–37. https://doi.org/10.1016/j.currproblcancer.2015.10.001

34. Grass GD, Krishna N, Kim S. The immune mechanisms of abscopal effect in radiation therapy. Curr Probl Cancer. 2016;40:10–24. https://doi.org/10.1016/j.currproblcancer.2015.10.003

35. Ng J, Dai T. Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med. 2016;4:118. https://doi.org/10.21037/atm.2016.01.32

36. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862–870. https://doi.org/ 10.1016/j.ijrobp.2003.09.012

37. Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park). 2008;22(9):1064-1084.

38. Daly ME, Monjazeb AM, Kelly K. Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer. J Thorac Oncol. 2015;10:1685–1693. https://doi.org/10.1097/JTO. 0000000000000686.

39. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–695. https://doi.org/10.1172/JCI67313

40. Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2017;12:1085–1097. https://doi.org/10.1016/j.jtho.2017.04.014

41. Herter-Sprie GS, Koyama S, Korideck H, Hai J, Deng J, Li YY, et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016;1:e87415. https://doi.org/10.1172/jci.insight.87415.

42. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74:5458–68. https://doi.org/10.1158/0008-5472

43. Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res. 2017;23:5514–26. https://doi.org/10.1158/1078-0432

44. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–377. https://doi.org/10.1038/nature14292

45. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–1755. https://doi.org/10.1056/NEJMoa1609214.

46. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Özgüroğlu M, Antonia SJ. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol. 2020;15(2):288-293. doi: 10.1016/j.jtho.2019.10.002.

47. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903. https://doi.org/10.1016/S1470-2045(17)30380-7.

48. Durm GA, Johnson C, Jalal SI, Sadiq AA, Jabbour SS, Zon R, et al. Safety and feasibility of consolidation pembrolizumab following concurrent chemoradiation for unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179. J Clin Oncol. 2017; 35(suppl):abstr 8523.

49. Tamiya A, Tamiya M, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, et al. Correlation of radiation pneumonitis history before nivolumab with onset of interstitial lung disease and progression-free survival of patients with pre-treated advanced non-small cell lung cancer. Anticancer Res. 2017;37(9):5199–5205. https://doi.org/10.21873/anticanres.11943.

50. Kataoka Y, Ebi N, Fujimoto D, Hara S, Hirano K, Narabayashi T, et al. Prior radiotherapy does not predict nivolumab response in non-small-cell lung cancer: a retrospective cohort study. Ann Oncol. 2017;28(6):1402. https://doi.org/10.1093/annonc/mdx114

51. Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(2):344–51. https://doi.org/10.1016/j.ijrobp.2017.02.003

52. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59–68. https://doi.org/10.1016/S1470-2045(13)70510-2.

53. Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, et al. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015;26(6):1134–1142. https://doi.org/10.1093/annonc/mdv104.

54. Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51:2321–2329. https://doi.org/10.1016/j.ejca.2015.07.035.

55. Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 2011; 17:6847–6857. https://doi.org/10.1158/1078-0432.CCR-11-1385

56. Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795–803. https://doi.org/10.1016/S1470-2045(15)00054-6

57. Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015; 16 (7):795–803. https://doi.org/10.1016/S1470-2045(15)00054-6

58. Fujimoto D, Uehara K, Sato Y, Sakanoue I, Ito M, Teraoka S, et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep. 2017:7:11373. https://doi.org/10.1038/s41598-017-11949-9

59. Hecht M, Buttner-Herold M, Erlenbach-Wunsch K, Haderlein M, Croner R, Grützmann R, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer. 2016;65:52–60.

60. Lim SH, Hong M, Ahn S, Choi YL, Kim KM, Oh D, et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer. 2016;52:1–9. https://doi.org/10.1016/j.ejca.2015.09.019

61. Schoenhals JE, Seyedin SN, Anderson C, Brooks ED, Li YR, Younes AI, et al. Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res. 2017;6;148 –158. https://doi.org/10.21037/tlcr.2017.03.06


Для цитирования:


Смоленов Е.И. Возможности сочетания иммунотерапии с лучевой терапией в лечении больных неоперабельным местно-распространённым немелкоклеточным раком легкого. Обзор литературы. Исследования и практика в медицине. 2021;8(2).

Просмотров: 19


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2409-2231 (Print)
ISSN 2410-1893 (Online)